In advanced NSCLC, patients treated with nivolumab, with or without the CTLA-4 blocker ipilimumab, or pembrolizumab, the median overall survival in the TP53-mutated group was 18.1 months, vs. 8.1 in the TP53-wild-type group. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.